Fabrice Barlesi
Prof Fabrice Barlesi is an expert in Oncology at Institut Gustave Roussy (France). As of October 2026, ScienceLeadR ranks Fabrice Barlesi in the top 1% of experts worldwide for Bronchial Neoplasms, Lung Neoplasms and Thoracic Neoplasms. Fabrice Barlesi has authored 1,046 publications, the most recent in 2026, and is an investigator in 90 clinical trials, 13 of them ongoing. SLR score: 5,030 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Pulmonology - Biochemistry - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2001 - 2026
Number : 1046
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Access to early-phase oncology trials: Trajectories and outcomes of more than 26,000 patients referred to a high-volume phase I unit. PMID 42762559 — cells, pharmaceutical preparations, neoplasms, therapeutics | Eur J Cancer | 2026 | 0 |
| Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRAS G12C mutations. PMID 42745627 — cells, language, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, mutation | Future Oncol | 2026 | 0 |
| Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial. PMID 42636834 — cells, quality of life, lung, disease-free survival, safety, blood, neoplasms, carcinoma, non-small-cell lung, drug therapy, drug-related side effects and adverse reactions, lung neoplasms, small cell lung carcinoma, therapeutics, chemotherapy | Lancet Oncol Top journal | 2026 | 0 |
| Patient-reported outcomes with adagrasib in KRYSTAL-12. PMID 42624145 — patient reported outcome measures | Lancet Top journal | 2026 | 0 |
| Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC. PMID 42532338 — research design, neoplasms, carcinoma, non-small-cell lung, uncertainty, therapeutics, rna | J Thorac Oncol | 2026 | 0 |
Clinical Studies 90
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
13 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study of pre and post surgery treatment with IPH5201 and durvalumab in participants with lung cancer (MATISSE) 2023-507778-42-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, neoadjuvant therapy, therapeutics | Phase 2 | Recruiting | 2023 |
| Rollover study for participants who are currently being treated with and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments 2025-523537-26-00 — cells, lung, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, therapeutics, mutation | Phase 1/Phase 2 | Recruiting | 2026 |
| Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated Locally Advanced or Metastatic Non squamous NSCLC with KRAS G12C Mutation (KRYSTAL 4) 2024-515698-85-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, mutation, chemotherapy | Phase 3 | Recruiting | 2025 |
| A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer (PACIFIC 9) 2023-503999-24-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, therapeutics | Phase 3 | Active not recruiting | 2022 |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C mutant Non Small Cell Lung Cancer NCT06890598 — cells, lung, safety, neoplasms, carcinoma, non-small-cell lung, immunotherapy, lung neoplasms, small cell lung carcinoma, carcinoma | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map